Forte Biosciences, Inc. carries no debt; cash flow comfortably covers obligations.

Forte Biosciences, Inc.'s free cash flow has decreased 65.67% from $-30.78M last year to $-51.00M, signaling decreasing performance

Forte Biosciences, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Forte Biosciences, Inc. has insufficient data to evaluate this check.

Forte Biosciences, Inc. has a net cash position, so leverage is healthy.

Forte Biosciences, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Forte Biosciences, Inc. has insufficient data to evaluate this check.

Forte Biosciences, Inc.'s short-term assets of $80.59M exceed its short-term liabilities of $20.75M

Forte Biosciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Forte Biosciences, Inc.'s return on equity of -106.16%, is lower than 15.00%, indicating bad performance

Forte Biosciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Forte Biosciences, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Forte Biosciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Forte Biosciences, Inc. has negative free cash flow, indicating cash burn

Forte Biosciences, Inc.'s yearly earnings has decreased 95.54% since last year from $-35.48M to $-69.38M, signaling decreasing performance

Forte Biosciences, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -176.64% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Forte Biosciences, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Forte Biosciences, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Forte Biosciences, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Forte Biosciences, Inc. has insufficient data to evaluate this check.

Forte Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Forte Biosciences, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Forte Biosciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Forte Biosciences, Inc. has insufficient data to evaluate this check.

Forte Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Forte Biosciences, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Forte Biosciences, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue